Marker Therapeutics grants 50,000 CEO options and 30,000 options each to three non-employee directors

Marker Therapeutics, Inc.

CEO Juan Vera awarded 50,000 stock options vesting annually over three years under 2020 Plan.
Non-employee directors David Eansor, Katherine Knobil, and Steven Elms each receive 30,000 options with same vesting.
Awards approved by Compensation Committee and Board on February 12, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.